Serious infections and cardiovascular complications among patients with chronic lymphocytic lymphoma treated with first-line ibrutinib or bendamustine/rituximab.

被引：0
|
作者：
Irwin, Debra E.
Thompson, Stephen
Ribalov, Rinat
Choudhry, Azhar
机构：
[1] IBM Watson Hlth, Cambridge, MA USA
[2] Teva Pharmaceut Inc, Parsippany, NJ USA
[3] Teva Pharmaceut Ind LTD, Petah Tiqwa, Israel
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.e19503
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e19503
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Plasmacytoid lymphoma treated with rituximab as first-line monotherapy
    I. Blancas López-Barajas
    Irene Zarcos
    Francisco J. Gómez
    María Teresa Delgado
    Josefa Carrillo
    Marta Legerén
    Belén Ríos
    Eduardo Pacios
    José Miguel Jurado
    María José Sánchez
    Rocío Fonseca
    José Luis García Puche
    Clinical and Translational Oncology, 2009, 11 : 704 - 706
  • [22] BENDAMUSTINE AND RITUXIMAB AS FIRST OR SECOND LINE THERAPY IN ELDERLY PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
    Gozzetti, A.
    Ciolli, S.
    Candi, V.
    Breschi, C.
    Fabbri, A.
    Schiattone, L.
    Cencini, E.
    Papini, G.
    Raspadori, D.
    Defina, M.
    Aprile, L.
    Bosi, A.
    Bocchia, M.
    HAEMATOLOGICA, 2014, 99 : 592 - 592
  • [23] Plasmacytoid lymphoma treated with rituximab as first-line monotherapy
    Blancas, Isabel
    Zarcos, Irene
    Gomez, Francisco J.
    Teresa Delgado, Maria
    Carrillo, Josefa
    Legeren, Marta
    Rios, Belen
    Pacios, Eduardo
    Miguel Jurado, Jose
    Jose Sanchez, Maria
    Fonseca, Rocio
    Garcia Puche, Jose Luis
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2009, 11 (10): : 704 - 706
  • [24] Survival Outcomes after First-Line Therapy in Follicular Lymphoma Patients Treated with Bendamustine and Rituximab Vs Other Rituximab Combinations in the United States
    Galaznik, Aaron
    Bell, Jill A.
    Hamilton, Laurie
    Ogbonnaya, Augustina
    Hennenfent, Kristin
    Eaddy, Michael T.
    Shou, Yaping
    BLOOD, 2017, 130
  • [25] NURSING EXPERIENCE WITH THE USE OF IBRUTINIB FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH HIGH-RISK CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA
    Haycraft, Dana
    O'Mary, Sharon
    Hsu, Emily
    Arthur, David
    Kipps, Thomas
    Stevens, Don
    ONCOLOGY NURSING FORUM, 2021, 48 (02)
  • [26] Combination therapy with fludarabine and rituximab followed by alemtuzumab in the first-line treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma
    Hainsworth, John D.
    Vazquez, Elizabeth R.
    Spigel, David R.
    Raefsky, Eric
    Bearden, James D.
    Saez, Ruben A.
    Greco, F. Anthony
    CANCER, 2008, 112 (06) : 1288 - 1295
  • [27] Benefit of rituximab maintenance after first-line bendamustine-rituximab in mantle cell lymphoma
    Wang, Yucai
    Larson, Melissa C.
    Kumar, Anita
    Hill, Brian T.
    Bond, David Alan
    Kahl, Brad S.
    Danilov, Alexey Valeryevich
    Merryman, Reid
    Grover, Natalie Sophia
    Tun, Aung M.
    Ayyappan, Sabarish Ram
    Pongas, Georgios
    Portell, Craig Anthony
    Munoz, Javier
    Reagan, Patrick Michael
    Moustafa, Muhamad Alhaj
    Pophali, Priyanka Avinash
    Greenwell, Irl Brian
    Cohen, Jonathon Brett
    Martin, Peter
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [28] Ibrutinib combined with bendamustine/rituximab (BR) in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): safety analysis in the HELIOS trial
    Cramer, Paula
    Chanan-Khan, Asher
    Fraser, Graeme
    Demirkan, Fatih
    Silva, Rodrigo Santucci
    Pylypenko, Halyna
    Grosicki, Sebastian
    Janssens, Ann
    Pristupa, Aleksander
    Goy, Andre
    Mayer, Jiri
    Dilhuydy, Marie-Sarah
    Loscertales, Javier
    Barlett, Nancy
    Avigdor, Abraham
    Rule, Simon
    Sun, Steven
    Phelps, Charles
    Mahler, Michelle
    Salman, Masha
    Howes, Angela
    Hallek, Michael
    LEUKEMIA & LYMPHOMA, 2015, 56 : 93 - 94
  • [29] Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL)
    Jain, Nitin
    Keating, Michael J.
    Thompson, Philip A.
    Ferrajoli, Alessandra
    Burger, Jan A.
    Borthakur, Gautam M.
    Takahashi, Koichi
    Estrov, Zeev E.
    Fowler, Nathan H.
    Kadia, Tapan M.
    Konopleva, Marina Y.
    Alvarado, Yesid
    Yilmaz, Musa
    DiNardo, Courtney D.
    Bose, Prithviraj
    Ohanian, Maro
    Pemmaraju, Naveen
    Jabbour, Elias
    Sasaki, Koji
    Kanagal-Shamanna, Rashmi
    Patel, Keyur
    Jorgensen, Jeffrey L.
    Wang, Sa A.
    Garg, Naveen
    Wang, Xuemei
    Sondermann, Katrina
    Cruz, Nichole
    Wei, Chongjuan
    Ayala, Ana
    Plunkett, William
    Kantarjian, Hagop M.
    Gandhi, Varsha
    Wierda, William G.
    BLOOD, 2019, 134
  • [30] Real-World Healthcare Resource Utilization in Patients with Indolent Non-Hodgkin's Lymphoma: Differences between Patients Treated First-Line with Ibrutinib or Bendamustine plus Rituximab
    Irwin, Debra
    Zhang, Lu
    Wilson, Kathleen
    Hoehn, Gerard
    Szabo, Erika
    Tang, Boxiong
    BLOOD, 2018, 132
12345